Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?
Authors:
- 14 July 2010
- journal article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 2 (5) , 331-342
Abstract
Vast preclinical and clinical evidence has made angiogenesis one of the hallmarks of cancer. In many human tumours, vascular endothelial growth factor (VEGF) has been identified as the crucial mediator of this process. Initial studies suggested that angiogenesis, and VEGF in particular, could be inhibited without the risk of major side effects. After the pivotal data in first-line studies in patients with colorectal cancer, numerous clinical trials have been undertaken in patients with breast cancer. This review attempts to update these investigations and define the role of anti-VEGF antibody treatment in advanced breast cancer.Keywords
This publication has 72 references indexed in Scilit:
- A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology GroupAnnals of Oncology, 2011
- North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancerAnnals of Oncology, 2009
- Angiogenesis is associated with the onset of hyperplasia in human ductal breast diseaseBritish Journal of Cancer, 2009
- A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic BiomarkersClinical Cancer Research, 2009
- Gene Expression Profile and Angiogenic Markers Correlate with Response to Neoadjuvant Bevacizumab Followed by Bevacizumab plus Chemotherapy in Breast CancerClinical Cancer Research, 2008
- Vascularization in Primary Breast Carcinomas: Its Prognostic Significance and Relationship with Tumor Cell DisseminationClinical Cancer Research, 2008
- VEGF Inhibition and Renal Thrombotic MicroangiopathyNew England Journal of Medicine, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Mechanisms of adverse effects of anti-VEGF therapy for cancerBritish Journal of Cancer, 2007
- Abnormal blood vessel development and lethality in embryos lacking a single VEGF alleleNature, 1996